分岐鎖アミノ酸トランスアミナーゼは,腫瘍治療における有望な標的として
Weiran Zhang1, Jie Shen1, Xuanyin Ding1
1Department of Thoracic Oncology, Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Frontiers in cell and developmental biology
|February 20, 2026
まとめ
枝分かれ鎖アミノ酸トランスアミナーゼ (BCATs) は,代謝とシグナル伝達を変えることで,がんの成長と薬剤耐性を促進します. BCATをターゲットにすることは,治療抵抗性を克服し,がん治療の結果を改善するための有望な戦略です.
科学分野:
- バイオケミストリー バイオケミストリー
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
背景:
- 枝分かれ鎖アミノ酸トランスアミナーゼ (BCAT),特にBCAT1とBCAT2は,枝分かれ鎖アミノ酸 (BCAA) 代謝における重要な酵素である.
- 異常なBCAT発現は,胃がん,臓がん,肺がん,乳がんを含む多数の癌の発生と進行に関与しています.
研究 の 目的:
- 癌の進行におけるBCATの多面的な役割を検討し,がん発生経路と代謝再プログラムへの影響を含む.
- 様々な癌の種類における治療抵抗に対するBCATの貢献を調査する.
- ガン治療のためのBCATを標的とした現在のおよび潜在的な治療戦略を要約する.
主な方法:
- 癌におけるBCATに関する現在の研究を統合した文献レビュー.
- 重要なシグナル伝達経路 (mTOR,PI3K/AKT,Wnt/β-catenin) に関するBCATの関与の分析.
- 代謝の再プログラム,表遺伝学,免疫回避におけるBCATの役割の検討.
主要な成果:
- BCATはBCAAの代謝を調節し,腫瘍性信号伝達経路に影響を与え,腫瘍の増殖,侵入,転移を促進します.
- BCATは,化学療法,標的療法,および様々な悪性腫瘍における内分泌療法に対する耐性に関連しています.
- BCATは,腫瘍の微環境における代謝適応,表遺伝的変異,免疫逃避に寄与する.
結論:
- BCATは,腫瘍発生と治療抵抗性の重要な原動力であり,潜在的なバイオマーカーと治療標的を表しています.
- 酵素阻害剤,ダイエット介入,または組み合わせた治療法を通じてBCATをターゲットにすることは,薬剤耐性を克服するために有望です.
- BCATメカニズムに関するさらなる研究は,がん治療における新しい臨床応用への道を開くことができます.
関連する概念動画
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)